Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.23.3
Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)
1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 03, 2022
USD ($)
shares
Aug. 01, 2022
USD ($)
shares
May 31, 2022
USD ($)
Feb. 28, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
shares
Dec. 31, 2022
USD ($)
Aug. 12, 2021
Jul. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
State of incorporation           DE        
Date of incorporation           Aug. 03, 2018        
Common stock, conversion description           minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.        
Common stock, conversion ratio           1        
Working capital           $ 2,483,179        
Accumulated deficit           (57,723,515)   $ (44,207,272)    
Cash           6,104,587   10,950,927    
Current liabilities           4,149,954   3,268,906    
Gross proceeds from sale of common stock $ 9,093,830   $ 99,999 $ 2,373,561     $ 2,473,560      
Cash equivalents           $ 0   $ 0    
IPO                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of common stock sold | shares   2,000,000                
Issuance of common shares   $ 1,099,360     $ 8,750,095          
Overallotment Option                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of common stock sold | shares 300,000                  
MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Ownership percentage by parent                 93.30%  
Minority stockholder ownership percentage                 6.70%  
MAIA Biotechnology, Inc. | MAIA Drug Development Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Ownership percentage by parent                   100.00%
DGD Pharmaceuticals Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
State of incorporation           DE        
Date of incorporation           Apr. 01, 2019        
MAIA Drug Development Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
State of incorporation           TX        
Date of incorporation           Sep. 10, 2018        
DGD or THIO                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of common stock sold | shares           248,969 0